$PODD News

5 Must-Read Analyst Questions From Insulet’s Q2 Earnings Call

Insulet (PODD) Q2 2026 Earnings Call Transcript

Insulet (PODD) Stock Looks Undervalued As The Market Stays Cautious

Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179

Insulet Valuation Attractive Despite Growth Reset Risk, RBC Says

Leerink Partners Downgrades Insulet to Market Perform, Lowers Price Target to $145

TD Cowen Maintains Hold on Insulet, Lowers Price Target to $144

UBS Maintains Neutral on Insulet, Lowers Price Target to $150

RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $160

Bernstein Maintains Outperform on Insulet, Lowers Price Target to $175

Benchmark Maintains Buy on Insulet, Lowers Price Target to $185

Stifel Maintains Buy on Insulet, Lowers Price Target to $180

Insulet Corporation Is Getting Closer To An Upgrade After Its Large Plunge

These Analysts Slash Their Forecasts On Insulet After Q2 Results

Wells Fargo Downgrades Insulet to Equal-Weight, Lowers Price Target to $144

JP Morgan Downgrades Insulet to Neutral, Lowers Price Target to $152

BTIG Downgrades Insulet to Neutral

Truist Securities Downgrades Insulet to Hold, Lowers Price Target to $153

Insulet (PODD) Is Down 21.9% After Cutting 2026 Revenue Outlook On Weaker Type 2 Retention

Insulet Stock Crashes as Tiny Guidance Cut Changes the Story